Abstract: Some embodiments provide a non-transitory machine-readable medium that stores a program executable by a device. The program identifies a set of visualizations associated with the user. The program further determines, for each visualization in the set of visualizations, a score associated with changes in the visualization. The program also determines a subset of the set of visualizations based on the set of scores. The program further provides to the user notifications associated with the subset of the set of visualizations.

Abstract: Some embodiments provide a non-transitory machine-readable medium that stores a program executable by a device. The program identifies a set of visualizations associated with the user. The program further determines, for each visualization in the set of visualizations, a score associated with changes in the visualization. The program also determines a subset of the set of visualizations based on the set of scores. The program further provides to the user notifications associated with the subset of the set of visualizations.

Abstract: A method may include: generating, by a controller, a first user interface configured to control selection of a first attribute from a set of attributes; generating, by the controller, a second user interface generated based on the controlled selection of the first attribute, the second user interface configured to enable selection of values with respect to the first attribute; generating, by the controller, a first query to enable querying at the database based on the one or more values with respect to the first attribute; generating, by the controller, a second query for execution at the database, when the first query fails to respond with a match, the second query including a first vector representative of a profile to enable querying the database; and generating, in response to the first query and/or the second query, a third user interface indicative of a result.

Abstract: In an example embodiment, a bundle loader is run in response to a communication from an application. The communication may indicate that the plurality of bundles of components in the application is to be executed. The plurality of bundles may include at least one bundle having a component that depends on a dependency component in another of the plurality of bundles. A configuration file indicating a set of the plurality of bundles to load in the bundle loader is received. The bundle loader is operated to load a bundle manifest for each bundle in the set of the plurality of bundles to load. Then, for each of the bundles in the set of plurality of bundles to load, the bundle is activated if no unactivated dependency component exists for any component in the bundle.

Abstract: In an example embodiment, a bundle loader is run in response to a communication from an application. The communication may indicate that the plurality of bundles of components in the application is to be executed. The plurality of bundles may include at least one bundle having a component that depends on a dependency component in another of the plurality of bundles. A configuration file indicating a set of the plurality of bundles to load in the bundle loader is received. The bundle loader is operated to load a bundle manifest for each bundle in the set of the plurality of bundles to load. Then, for each of the bundles in the set of plurality of bundles to load, the bundle is activated if no unactivated dependency component exists for any component in the bundle.

Abstract: Alkynyl pyrrolo [2,3-d] pyrimidines of Formula I are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.

Abstract: An optical switch system for dropping a ROADM node is presented. The switch system includes an N×M structure having two layers. A first layer includes optical splitters, each splitter receiving a multiplexed input signal and outputting a first multiplexed output signal. A second layer includes switches receiving the first multiplexed output signals from the optical splitters and generating a second multiplexed output signal. The second multiplexed output signal is typically one of the first multiplexed output signals. An optional third layer, which includes optical filters, receives the second multiplexed output signal from the switches and produces a non-multiplexed, single-wavelength output signal.

Abstract: An optical switch system for dropping a ROADM node is presented. The switch system includes an N×M structure having two layers. A first layer includes optical splitters, each splitter receiving a multiplexed input signal and outputting a first multiplexed output signal. A second layer includes switches receiving the first multiplexed output signals from the optical splitters and generating a second multiplexed output signal. The second multiplexed output signal is typically one of the first multiplexed output signals. An optional third layer, which includes optical filters, receives the second multiplexed output signal from the switches and produces a non-multiplexed, single-wavelength output signal.

Abstract: Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.

Abstract: Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.

Abstract: Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.

Abstract: Pyrrolopyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Methods of synthesis and use of such compounds are also described and claimed.

Abstract: Novel purine compounds of Formula I. and tautomers, pharmaceutically acceptable salts, and prodrugs thereof, wherein X is S, S(O), or S(O)2; and O is selected from alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl, and heterocyclic, all optionally substituted, are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.

Abstract: Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same. Methods of using the novel purine compounds of the invention, and tautomers and pharmaceutically acceptable salts thereof, include their use in inhibiting heat shock protein 90's (HSP90's) to thereby treat or prevent HSP90-dependent diseases, e.g., proliferative disorders such as breast cancer.

Abstract: The present invention provides compounds represented by Formula I.

Abstract: Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.

Abstract: Pyrrolopyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Methods of synthesis and use of such compounds are also described and claimed.

Abstract: Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.